Register Login

All Posts

Oct 30 2026
george

October 2026 QQ: Anti-Phospholipid Antibody Summary

Our October 2026 quiz, with 32 respondents, asked, “Which is NOT an antiphospholipid antibody?” The answers reveal participants’ wisdom: Anti beta-2 glycoprotein 1: 1 (3%) Alpha-2 antiplasmin: 23 (72%) Lupus anticoagulant: 1 (3%) Antiprothrombin: 7 (22%) Anticardiolipin: 0 The only mislead that attracted respondents was antiprothrombin, a relatively rare APL that is associated with bleeding. […]
read more
Comments (0)
Quick Question Archive
Oct 28 2026
george

Should We Publish Measurement Uncertainty Data?

Check with your medical library for MacDonald S. Measurement uncertainty in the hemostasis laboratory. Semin Thromb Hemost. 2026;52(8):899-907. doi: 10.1055/a-2723-9166. PMID: 41109209. Abstract Clinical laboratory results are inherently uncertain. Variability arises when repeating measurements of the same sample under different conditions. Measurement uncertainty (MU) is a metrological framework that quantifies this variability, enabling clinical interpretation […]
read more
Comments (0)
Validation
Oct 28 2026
george

Historical Review Describing Hemorrhage and Thrombosis

Check with your local medical library for Franchini M, Zani M, Focosi D. Human evolution: between hemorrhage and thrombosis. Semin Thromb Hemost. 2026. doi: 10.1055/a-2905-4308. PMID: 42398954. Abstract The human coagulation system has resulted from thousands of years of evolutionary pressure, finely balancing the competing risks of lethal hemorrhage and catastrophic thrombosis. There are several […]
read more
Comments (0)
Bleeding Disorders
Oct 28 2026
george

Illustrated Review: History of Anticoagulant Pharmacology

Here’s an open-access illustrated review that includes FXI and FXII inhibitors currently in development: Wichaiyo S. Pharmacology of anticoagulants: from heparin to novel target-specific agents. J Thromb Haemost. 2026:S1538-7836(26)00486-1. doi: 10.1016/j.jtha.2026.08.001. PMID: 42567362. Abstract Anticoagulants are the drugs of choice for the management of various thromboembolic disorders affecting both arteries and veins. This review delineates […]
read more
Comments (0)
Anticoagulant Therapy
Oct 27 2026
george

A Meta-Analysis: Microplastics, Nanoplastics, and Thrombogenesis

Thanks to Dr. Emmanuel Favaloro for featuring this provocative open-access meta-analysis connecting microplastics and hemostasis. Balwan R, Hew YY, Gurumurthy G, et al. Microplastics, nanoplastics, and thrombogenesis. Res Pract Thromb Haemost. 2026;10(7):106931. doi: 10.1016/j.rpth.2026.106931. PMID: 42894845; PMCID: PMC13677222. Abstract Micro- and nanoplastics (MNPs) are produced through mechanical, chemical, and ultraviolet-mediated degradation of plastics and may […]
read more
Comments (0)
Thrombophilia
Oct 27 2026
george

Summary–Current Hemophilia Therapy: FVIII Bypassing and Rebalancing

Click for an illustrated outline in Hemophilia Today, “The Rebalanced Patient: New Therapies and New Thrombotic Risks in Hemophilia.” Introduction For decades, the central therapeutic principle in hemophilia was straightforward: replace what was missing. In hemophilia A, this meant replacing FVIII; in hemophilia B, FIX. Prophylactic factor replacement transformed hemophilia from a condition dominated by recurrent […]
read more
Comments (0)
Bleeding Disorders
Load more

George Fritsma MS MLS

George Fritsma is a medical laboratory scientist, educator, and author. George  is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

read more

Cheat Sheets from George

Name

Questions or Comments?

Email George

Quick Question

Which is an antifibrinolytic used to control bleeding?